The monoclonal antibody market is projected to reach US$ 243.05 billion by 2028 from US$ 111.01 billion in 2021; it is expected to grow at a CAGR of 11.8% from 2021 to 2028. The increasing prevalence of cancer and other chronic diseases and the growing cases of COVID-19 across various regions are the factors supporting the market proliferation. According to the World Cancer Research Fund and American Institute for Cancer, in 2020, ~18.1 million cancer cases were recorded worldwide, including 9.3 million cases in men and 8.8 million cases in women. Various types of monoclonal antibodies are being adopted for the treatment of different cancer types, and a few of these products are still in phases 2 and 3 clinical trials. Thus, the rising prevalence of chronic diseases has raised the demand for monoclonal antibodies across the world.
The monoclonal antibodies market is segmented on the basis of source, production method, indication application, and end-user. Based on source, the market is segmented into murine, chimeric, human, and humanized. The human segment is estimated to account for the largest market share during 2021-2028. The market growth of this segment is attributed to the rise on account of the integration of human monoclonal antibodies for the treatment of various kinds of infectious diseases. For instance, Regeneron launched FDA approved antibody cocktail casirivimab and imdevimab together for use in COVID-19. The drug has received Emergency Use Authorization (EUA) from FDA. It is used for the treatment of mild to moderate COVID-19 in adults as well as in pediatric patients at least 12 years of age and weighing at least 40kg. Moreover, an increase in their use in various chronic diseases and employment of advanced genetic engineering technology are among the significant factors driving the market segment's growth.
By indication, the monoclonal antibodies market is segmented into cancer, autoimmune diseases, inflammatory diseases, infectious disease, microbial disease, and others. The cancer segment is expected to dominate the market during the forecast periodAdvancements related to the therapeutic application of monoclonal antibodies have enabled their successful implementation in the treatments of various cancer types, such as breast cancer, lung cancer, and colon cancer. Drugs based on these antibodies help in flagging cancer cells, triggering cell-membrane destruction, blocking immune system inhibitors, and so on. The FDA, in June 2020, approved two drugs - olaparib and rucaparib - for the treatment of prostate cancer. The drug is especially effective among men with prostate cancer conditions that have spread or metastasized and has stopped responding to standard hormone treatments, i.e., castration-resistant disease condition.
By end-user, the monoclonal antibody market is segmented into hospitals, research institutes, and others. The hospital segment holds the largest market share owing to the increasing adoption mABs as a preferred line of treatment against cancer.
The World Health Organization (WHO), World Cancer Research Fund International, Organization for Economic Co-operation and Development (OECD), Centers for Medicare & Medicaid Services (CMS), US Department of Health and Human Services, National Institute of Health (NIH), and American Institute of Cancer are among the primary and secondary sources referred to while preparing the report on the monoclonal antibodies market.
Reasons to Buy
The monoclonal antibodies market is segmented on the basis of source, production method, indication application, and end-user. Based on source, the market is segmented into murine, chimeric, human, and humanized. The human segment is estimated to account for the largest market share during 2021-2028. The market growth of this segment is attributed to the rise on account of the integration of human monoclonal antibodies for the treatment of various kinds of infectious diseases. For instance, Regeneron launched FDA approved antibody cocktail casirivimab and imdevimab together for use in COVID-19. The drug has received Emergency Use Authorization (EUA) from FDA. It is used for the treatment of mild to moderate COVID-19 in adults as well as in pediatric patients at least 12 years of age and weighing at least 40kg. Moreover, an increase in their use in various chronic diseases and employment of advanced genetic engineering technology are among the significant factors driving the market segment's growth.
By indication, the monoclonal antibodies market is segmented into cancer, autoimmune diseases, inflammatory diseases, infectious disease, microbial disease, and others. The cancer segment is expected to dominate the market during the forecast periodAdvancements related to the therapeutic application of monoclonal antibodies have enabled their successful implementation in the treatments of various cancer types, such as breast cancer, lung cancer, and colon cancer. Drugs based on these antibodies help in flagging cancer cells, triggering cell-membrane destruction, blocking immune system inhibitors, and so on. The FDA, in June 2020, approved two drugs - olaparib and rucaparib - for the treatment of prostate cancer. The drug is especially effective among men with prostate cancer conditions that have spread or metastasized and has stopped responding to standard hormone treatments, i.e., castration-resistant disease condition.
By end-user, the monoclonal antibody market is segmented into hospitals, research institutes, and others. The hospital segment holds the largest market share owing to the increasing adoption mABs as a preferred line of treatment against cancer.
The World Health Organization (WHO), World Cancer Research Fund International, Organization for Economic Co-operation and Development (OECD), Centers for Medicare & Medicaid Services (CMS), US Department of Health and Human Services, National Institute of Health (NIH), and American Institute of Cancer are among the primary and secondary sources referred to while preparing the report on the monoclonal antibodies market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the medical laser systems market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global monoclonal antibodies market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Monoclonal Antibodies (mAbs) Market - By Source
1.3.2 Global Monoclonal Antibodies (mAbs) Market - By Production Method
1.3.3 Global Monoclonal Antibodies (mAbs) Market - By Indication
1.3.4 Global Monoclonal Antibodies (mAbs) Market - By Application
1.3.5 Global Monoclonal Antibodies (mAbs) Market - By End-User
1.3.6 Global Monoclonal Antibodies (mAbs) Market - By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Monoclonal Antibodies (mAbs) Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East And Africa PEST Analysis
4.2.5 South And Central America PEST Analysis
4.3 Experts Opinion
5. Monoclonal Antibodies (mAbs) Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Cancer and Other Chronic Diseases
5.1.2 mABs Uptake Proves to be Effective During Pandemic Outbreak
5.2 Market Restraints
5.2.1 Low Awareness, Accessibility, and High Cost
5.3 Market Opportunities
5.3.1 Cost-effective Advanced Technology for Developing mABs Presents Billion-Dollar Opportunity
5.4 Future Trends
5.4.1 Strategic Research Collaborations
5.5 Impact Analysis
6. Monoclonal Antibodies (mAbs) Market- Global Analysis
6.1 Global Monoclonal Antibodies (mAbs) Market Revenue Forecast and Analysis
6.2 Global Monoclonal Antibodies (mAbs) Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
7. Global Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028- by Source
7.1 Overview
7.2 Global Monoclonal Antibodies (mAbs) Market, By Source, 2021 & 2028 (%)
7.3 Murine
7.3.1 Overview
7.3.2 Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.4 Chimeric
7.4.1 Overview
7.4.2 Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.5 Humanized
7.5.1 Overview
7.5.2 Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.6 Human
7.6.1 Overview
7.6.2 Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
8. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 - Production Method
8.1 Overview
8.2 Global Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2021 & 2028 (%)
8.3 In-Vivo
8.3.1 Overview
8.3.2 In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
8.4 In-Vitro
8.4.1 Overview
8.4.2 In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 - Indication
9.1 Overview
9.2 Global Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2021 & 2028 (%)
9.3 Cancer
9.3.1 Overview
9.3.2 Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.4 Autoimmune Diseases
9.4.1 Overview
9.4.2 Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.5 Inflammatory Diseases
9.5.1 Overview
9.5.2 Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.6 Infectious Diseases
9.6.1 Overview
9.6.2 Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.7 Microbial Diseases
9.7.1 Overview
9.7.2 Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 - Application
10.1 Overview
10.2 Global Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2021 & 2028 (%)
10.3 Diagnostic Applications
10.3.1 Overview
10.3.2 Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10.4 Therapeutic Applications
10.4.1 Overview
10.4.2 Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10.5 Research Applications
10.5.1 Overview
10.5.2 Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 - End-User
11.1 Overview
11.2 Global Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2021 & 2028 (%)
11.3 Hospitals
11.3.1 Overview
11.3.2 Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11.4 Research Institutes
11.4.1 Overview
11.4.2 Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11.5 Others
11.5.1 Overview
11.5.2 Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
12. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 - Geographical Analysis
12.1 North America: Monoclonal Antibodies (mAbs) Market
12.1.1 Overview
12.1.2 North America: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
12.1.3 North America: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (US$ Million)
12.1.4 North America: Monoclonal Antibodies (mAbs) Market, by Production, 2019-2028 (US$ Million)
12.1.5 North America: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (US$ Million)
12.1.6 North America: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (US$ Million)
12.1.7 North America: Monoclonal Antibodies (mAbs) Market, by End-User, 2019-2028 (US$ Million)
12.1.8 North America: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)
12.1.8.1 US: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
12.1.8.1.1 Overview
12.1.8.1.2 US: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
12.1.8.1.3 US: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (US$ Million)
12.1.8.1.4 US: Monoclonal Antibodies (mAbs) Market, by Production, 2019-2028 (US$ Million)
12.1.8.1.5 US: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (US$ Million)
12.1.8.1.6 US: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (US$ Million)
12.1.8.1.7 US: Monoclonal Antibodies (mAbs) Market, by End-User, 2019-2028 (US$ Million)
12.1.8.2 Canada: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
12.1.8.2.1 Overview
12.1.8.2.2 Canada: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
12.1.8.2.3 Canada: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (US$ Million)
12.1.8.2.4 Canada: Monoclonal Antibodies (mAbs) Market, by Production, 2019-2028 (US$ Million)
12.1.8.2.5 Canada: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (US$ Million)
12.1.8.2.6 Canada: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (US$ Million)
12.1.8.2.7 Canada: Monoclonal Antibodies (mAbs) Market, by End-User, 2019-2028 (US$ Million)
12.1.8.3 Mexico: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
12.1.8.3.1 Overview
12.1.8.3.2 Mexico: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
12.1.8.3.3 Mexico: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (US$ Million)
12.1.8.3.4 Mexico: Monoclonal Antibodies (mAbs) Market, by Production, 2019-2028 (US$ Million)
12.1.8.3.5 Mexico: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (US$ Million)
12.1.8.3.6 Mexico: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (US$ Million)
12.1.8.3.7 Mexico: Monoclonal Antibodies (mAbs) Market, by End-User, 2019-2028 (US$ Million)
12.2 Europe: Monoclonal Antibodies (mAbs) Market
12.2.1 Overview
12.2.2 Europe: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.3 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.2.4 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
12.2.5 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
12.2.6 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
12.2.7 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
12.2.8 Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)
12.2.8.1 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.8.1.1 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.8.1.2 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.2.8.1.3 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
12.2.8.1.4 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
12.2.8.1.5 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
12.2.8.1.6 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Product (US$ Million)
12.2.8.1.7 Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
12.2.8.2 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.8.2.1 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.8.2.2 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.2.8.2.3 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
12.2.8.2.4 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
12.2.8.2.5 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
12.2.8.2.6 UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User US$ Million)
12.2.8.3 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.8.3.1 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.8.3.2 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.2.8.3.3 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
12.2.8.3.4 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
12.2.8.3.5 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
12.2.8.3.6 France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
12.2.8.4 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.8.4.1 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.8.4.2 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.2.8.4.3 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
12.2.8.4.4 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
12.2.8.4.5 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
12.2.8.4.6 Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
12.2.8.5 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.8.5.1 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.8.5.2 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.2.8.5.3 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
12.2.8.5.4 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
12.2.8.5.5 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
12.2.8.5.6 Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
12.2.8.6 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.8.6.1 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.2.8.6.2 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source(US$ Million)
12.2.8.6.3 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
12.2.8.6.4 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication(US$ Million)
12.2.8.6.5 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application(US$ Million)
12.2.8.6.6 Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
12.3 Asia Pacific Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028
12.3.1 Overview
12.3.2 Asia Pacific: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.3 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
12.3.4 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019-2028 (USD Million)
12.3.5 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (USD Million)
12.3.6 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (USD Million)
12.3.7 Asia Pacific: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
12.3.8 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)
12.3.8.1 China: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.8.1.1 China: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.8.1.2 China: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
12.3.8.1.3 China: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019-2028 (USD Million)
12.3.8.1.4 China: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (USD Million)
12.3.8.1.5 China: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (USD Million)
12.3.8.1.6 China: Monoclonal Antibodies (mAbs) Market, by Product, 2019-2028 (USD Million)
12.3.8.1.7 China: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
12.3.8.2 Japan: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.8.2.1 Japan: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.8.2.2 Japan: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
12.3.8.2.3 Japan: Monoclonal Antibodies (mAbs) Market, by Product, 2019-2028 (USD Million)
12.3.8.2.4 Japan: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019-2028 (USD Million)
12.3.8.2.5 Japan: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (USD Million)
12.3.8.2.6 Japan: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (USD Million)
12.3.8.2.7 Japan: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
12.3.8.3 India: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.8.3.1 India: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.8.3.2 India: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
12.3.8.3.3 India: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019-2028 (USD Million)
12.3.8.3.4 India: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (USD Million)
12.3.8.3.5 India: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (USD Million)
12.3.8.3.6 India: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
12.3.8.4 South Korea: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.8.4.1 South Korea: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.8.4.2 South Korea: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
12.3.8.4.3 South Korea: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019-2028 (USD Million)
12.3.8.4.4 South Korea: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (USD Million)
12.3.8.4.5 South Korea: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
12.3.8.5 Australia: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.8.5.1 Australia: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.8.5.2 Australia: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
12.3.8.5.3 Australia: Monoclonal Antibodies (mAbs) Market, By Production Method, 2019-2028 (USD Million)
12.3.8.5.4 Australia: Monoclonal Antibodies (mAbs) Market, By Indication, 2019-2028 (USD Million)
12.3.8.5.5 Australia: Monoclonal Antibodies (mAbs) Market, By Application, 2019-2028 (USD Million)
12.3.8.5.6 Australia: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
12.3.8.6 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.8.6.1 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.3.8.6.2 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Source, 2019-2028 (USD Million)
12.3.8.6.3 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019-2028 (USD Million)
12.3.8.6.4 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Indication, 2019-2028 (USD Million)
12.3.8.6.5 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Application, 2019-2028 (USD Million)
12.3.8.6.6 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, By End User, 2019-2028 (USD Million)
12.4 Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028
12.4.1 Overview
12.4.2 Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.4.3 Middle East & Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.4.4 Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)
12.4.5 Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
12.4.6 Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.4.7 Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
12.4.8 Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)
12.4.8.1 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.4.8.1.1 Overview
12.4.8.1.2 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.4.8.1.3 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.4.8.1.4 UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)
12.4.8.1.5 UAE: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
12.4.8.1.6 UAE: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.4.8.1.7 UAE: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
12.4.8.2 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.4.8.2.1 Overview
12.4.8.2.2 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.4.8.2.3 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.4.8.2.4 Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)
12.4.8.2.5 Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
12.4.8.2.6 Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.4.8.2.7 Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
12.4.8.3 South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.4.8.3.1 Overview
12.4.8.3.2 South Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.4.8.3.3 South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.4.8.3.4 South Africa: Metabolomics Market Revenue and Forecasts To 2028, By Production (US$ Million)
12.4.8.3.5 South Africa: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
12.4.8.3.6 South Africa: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.4.8.3.7 South Africa: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
12.5 South And Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028
12.5.1 Overview
12.5.2 South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.5.3 South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.5.4 South and Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)
12.5.5 South and Central America: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
12.5.6 South and Central America: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.5.7 South and Central America: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
12.5.8 South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)
12.5.8.1 Argentina Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.5.8.1.1 Overview
12.5.8.1.2 Argentina Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.5.8.1.3 Argentina: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.5.8.1.4 Argentina: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)
12.5.8.1.5 Argentina: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
12.5.8.1.6 Argentina: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.5.8.1.7 Argentina: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
12.5.8.2 Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.5.8.2.1 Overview
12.5.8.2.2 Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
12.5.8.2.3 Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.5.8.2.4 Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)
12.5.8.2.5 Brazil: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
12.5.8.2.6 Brazil: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.5.8.2.7 Brazil: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
12.5.8.3 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market- Revenue and Forecast to 2028 (USD Mn)
12.5.8.3.1 Overview
12.5.8.3.2 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market- Revenue and Forecast to 2028 (USD Mn)
12.5.8.3.3 Rest of South & Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
12.5.8.3.4 Rest of South & Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)
12.5.8.3.5 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
12.5.8.3.6 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
12.5.8.3.7 Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
13. Impact Of COVID-19 Pandemic on Monoclonal Antibodies (mAbs) Market
13.1 North America: Impact Assessment of COVID-19 Pandemic
13.2 Europe: Impact Assessment of COVID-19 Pandemic
13.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
13.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
13.5 South and Central America: Impact Assessment of COVID-19 Pandemic
14. Monoclonal Antibodies (mAbs) Market-Industry Landscape
14.1 Overview
14.2 Growth Strategies Done by the Companies in the Market, (%)
14.3 Organic Developments
14.3.1 Overview
14.4 Inorganic Developments
14.4.1 Overview
15. Company Profiles
15.1 Novartis AG
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Pfizer Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 GlaxoSmithKline plc
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Amgen Inc
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 DAIICHI SANKYO COMPANY LIMITED
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 F. HOFFMANN-LA ROCHE LTD
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 AstraZeneca
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Eli Lilly and Company
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Bayer AG
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Bristol-Myers Squibb Company
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
16. Appendix
16.1 About The Publisher
16.2 Glossary of TermsList of Tables
Table 1. North America Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 2. North America Monoclonal Antibodies (mAbs) Market, by Production- Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Monoclonal Antibodies (mAbs) Market, by Indication- Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Monoclonal Antibodies (mAbs) Market, by Application- Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Monoclonal Antibodies (mAbs) Market, by End-User- Revenue and Forecast to 2028 (US$ Million)
Table 6. US Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 7. US Monoclonal Antibodies (mAbs) Market, by Production- Revenue and Forecast to 2028 (US$ Million)
Table 8. US Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 9. US Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 10. US Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada: Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 12. Canada Monoclonal Antibodies (mAbs) Market, by Production- Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 14. Canada Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 15. Canada Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 16. Mexico: Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 17. Mexico Monoclonal Antibodies (mAbs) Market, by Production- Revenue and Forecast to 2028 (US$ Million)
Table 18. Mexico Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 19. Mexico Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 20. Mexico Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 21. Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 22. Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
Table 23. Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
Table 24. Europe and Middle East and Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 25. Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
Table 26. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 27. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
Table 28. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
Table 29. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 30. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Product US$ Million)
Table 31. Germany Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
Table 32. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 33. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
Table 34. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
Table 35. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 36. UK Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User US$ Million)
Table 37. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 38. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
Table 39. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
Table 40. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 41. France Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
Table 42. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 43. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
Table 44. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
Table 45. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 46. Italy Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
Table 47. Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 48. Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
Table 49. Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
Table 50. Spain Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 51. Spain Monoclonal Antibodies (mAbs) Market, by End User - Revenue and Forecast to 2028 by End User (US$ Million)
Table 52. Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 53. Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production Method (US$ Million)
Table 54. Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Indication (US$ Million)
Table 55. Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 56. Rest of Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, by End User (US$ Million)
Table 57. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 58. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Production Method - Revenue and Forecast to 2028 (US$ Million)
Table 59. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 60. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 61. Asia Pacific Monoclonal Antibodies (mAbs) Market, By End User - Revenue and Forecast to 2028 (US$ Million)
Table 62. China Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 63. China Monoclonal Antibodies (mAbs) Market, by Production Method - Revenue and Forecast to 2028 (US$ Million)
Table 64. China Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 65. China Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 66. China Monoclonal Antibodies (mAbs) Market, by Product - Revenue and Forecast to 2028 (US$ Million)
Table 67. China Monoclonal Antibodies (mAbs) Market, By End User - Revenue and Forecast to 2028 (US$ Million)
Table 68. Japan Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 69. Japan Monoclonal Antibodies (mAbs) Market, by Product - Revenue and Forecast to 2028 (US$ Million)
Table 70. Japan Monoclonal Antibodies (mAbs) Market, by Production Method - Revenue and Forecast to 2028 (US$ Million)
Table 71. Japan Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 72. Japan Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 73. Japan Monoclonal Antibodies (mAbs) Market, By End User - Revenue and Forecast to 2028 (US$ Million)
Table 74. India Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 75. India Monoclonal Antibodies (mAbs) Market, by Production Method - Revenue and Forecast to 2028 (US$ Million)
Table 76. India Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 77. India Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 78. India Monoclonal Antibodies (mAbs) Market, By End User - Revenue and Forecast to 2028 (US$ Million)
Table 79. South Korea Monoclonal Antibodies (mAbs) Market, by Product - Revenue and Forecast to 2028 (US$ Million)
Table 80. South Korea Monoclonal Antibodies (mAbs) Market, by Production Method - Revenue and Forecast to 2028 (US$ Million)
Table 81. South Korea Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 82. South Korea Monoclonal Antibodies (mAbs) Market, By End User - Revenue and Forecast to 2028 (US$ Million)
Table 83. Australia Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 84. Australia Monoclonal Antibodies (mAbs) Market, By Production Method - Revenue and Forecast to 2028 (US$ Million)
Table 85. Australia Monoclonal Antibodies (mAbs) Market, By Indication - Revenue and Forecast to 2028 (US$ Million)
Table 86. Australia Monoclonal Antibodies (mAbs) Market, By Application - Revenue and Forecast to 2028 (US$ Million)
Table 87. Australia Monoclonal Antibodies (mAbs) Market, By End User - Revenue and Forecast to 2028 (US$ Million)
Table 88. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, by Source - Revenue and Forecast to 2028 (US$ Million)
Table 89. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, by Production Method - Revenue and Forecast to 2028 (US$ Million)
Table 90. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 91. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 92. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, By End User - Revenue and Forecast to 2028 (US$ Million)
Table 93. Middle East & Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 94. Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)
Table 95. Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 96. Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 97. Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 98. UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 99. UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)
Table 100. UAE: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 101. UAE: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 102. UAE: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 103. Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 104. Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)
Table 105. Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 106. Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 107. Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 108. South Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 109. South Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)
Table 110. South Africa: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 111. South Africa: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 112. South Africa: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 113. South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 114. South and Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)
Table 115. South and Central America: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 116. South and Central America: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 117. South and Central America: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 118. Argentina: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 119. Argentina: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)
Table 120. Argentina: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 121. Argentina: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 122. Argentina: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 123. Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 124. Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)
Table 125. Brazil: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 126. Brazil: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 127. Brazil: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 128. Rest of South & Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)
Table 129. Rest of South & Central America: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)
Table 130. Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 131. Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 132. Rest of South and Central America: Monoclonal Antibodies (mAbs) Market, by End-User - Revenue and Forecast to 2028 (US$ Million)
Table 133. Organic Developments Done by Companies
Table 134. Inorganic Developments Done by Companies
Table 135. Glossary of Terms
List of Figures
Figure 1. Monoclonal Antibodies (mAbs) Market Segmentation
Figure 2. Monoclonal Antibodies (mAbs) Market, By Region
Figure 3. Global Monoclonal Antibodies (mAbs) Market Overview
Figure 4. Human Segment Held Largest Share of Type Segment in Monoclonal Antibodies (mAbs) Market
Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Monoclonal Antibodies (mAbs) Market, by Geography (US$ Million)
Figure 7. Global Monoclonal Antibodies (mAbs) Market- Leading Country Markets (US$ Million)
Figure 8. Global Monoclonal Antibodies (mAbs) Market, Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East And Africa: PEST Analysis
Figure 13. South And Central America: PEST Analysis
Figure 14. Experts Opinion
Figure 15. Impact Analysis of Drivers and Restraints Pertaining to Monoclonal Antibodies (mAbs) Market
Figure 16. Global Monoclonal Antibodies (mAbs) Market- Revenue Forecast and Analysis - 2021 - 2028
Figure 17. Global Monoclonal Antibodies (mAbs) Market - By Geography Forecast and Analysis - 2021 - 2028
Figure 18. Market Positioning of Key Players in Global Monoclonal Antibodies (mAbs) Market
Figure 19. Global Monoclonal Antibodies (mAbs) Market, by Source, 2021 & 2028 (%)
Figure 20. Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 24. Global Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2021 & 2028 (%)
Figure 25. In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 26. In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 27. Global Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2021 & 2028 (%)
Figure 28. Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 29. Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 30. Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 31. Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 32. Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 33. Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 34. Global Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2021 & 2028 (%)
Figure 35. Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 36. Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 37. Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 38. Global Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2021 & 2028 (%)
Figure 39. Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 40. Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 41. Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 42. North America: Monoclonal Antibodies (mAbs) Market, by Key Country - Revenue (2021) (US$ Million)
Figure 43. North America Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
Figure 44. North America: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)
Figure 45. US: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
Figure 46. Canada: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
Figure 47. Mexico: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (US$ Million)
Figure 48. Europe: Monoclonal Antibodies (mAbs) Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 49. Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 50. Europe Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)
Figure 51. Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Key Country - Revenue (2021) (US$ Million)
Figure 52. Asia Pacific Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
Figure 53. Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 54. Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 55. Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)
Figure 56. UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 57. Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 58. South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 59. South and Central America Monoclonal Antibodies (mAbs) Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 60. South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 61. South and Central America Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)
Figure 62. Argentina Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 63. Brazil: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 64. Rest of South and Central America: Monoclonal Antibodies (mAbs) Market- Revenue and Forecast to 2028 (US$ Million)
Figure 65. Impact of COVID-19 Pandemic in North American Country Markets
Figure 66. Impact of COVID-19 Pandemic in European Country Markets
Figure 67. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 68. Impact of COVID-19 Pandemic in Middle East and Africa Country Markets
Figure 69. Impact Of COVID-19 Pandemic in South and Central America Africa Country Markets
Figure 70. Growth Strategies Done by the Companies in the Market, (%)
Companies Mentioned
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc
- Amgen, Inc
- Daiichi Sankyo Company, Limited
- F. Hoffmann-La Roche AG
- AstraZeneca
- Elli Lilly and Company
- Bayer AG
- Bristol-Myers Squibb Company
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 163 |
| Published | January 2022 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 111011.28 million |
| Forecasted Market Value ( USD | $ 243051.06 million |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
